Abstract

AbstractGlanzmann's thrombasthenia (GT) is an autosomal recessive inherited platelet function defect that characterized by reduction in, or absence of, platelet aggregation in response to multiple physiologic agonists. GT is characterized by normal platelet count, prolonged bleeding time, and abnormal clot retraction. The defect is caused by mutations in the genes encoding GPIIb or GPIIIa that result in qualitative or quantitative abnormalities of the platelet membrane GPIIb/IIIa. GT occurs in high frequency in certain ethnic populations with an increased incidence of consanguinity, such as Indians, Iranians, Iraqi Jews, Palastinian and Jordanian Arabs and French gypsies. Forty-five unrelated patients of GT were enrolled in the study to identify the causative molecular defects and also to correlate the genotype with the phenotype. Molecular modeling was performed for the novel missense mutations. The current study identifies 22 novel mutations in these patients. Missense mutations were identified as the defects responsible for most of the GT patients (59%). Even though missense was common, the study concludes that the genetic defect is heterogeneous in nature and difficult to design a DNA marker for carrier detection in GT.

Highlights

  • Glanzmann’s thrombasthenia (GT) is a hereditary platelet function defect, characterized by normal platelet count, prolonged bleeding time, and abnormal clot retraction

  • Absent or severely reduced clot retraction of 0% to 5%, was seen in 40 GT patients. 5 patients showed moderate clot retraction (>5%) and these patients were clinically mild

  • Leu318Ser missense mutation resulted in type I GT phenotype

Read more

Summary

Introduction

Glanzmann’s thrombasthenia (GT) is a hereditary platelet function defect, characterized by normal platelet count, prolonged bleeding time, and abnormal clot retraction. Platelet GPIIb/IIIa analysis by flow cytometry revealed 62.2%, 15.5% and 22.2% of GT to have types I, II and III respectively. The flow cytometry analysis revealed that the patient was GT type I since he had severely reduced expression GPIIb/IIIa on the platelets.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call